MINDSET-1

This study is testing whether an oral medication called KarXT + KarX-EC is safe and can help improve thinking and memory in people with mild to moderate Alzheimer’s disease.

People who meet the following criteria may be eligible to participate in this study;

• aged 60 - 85 years
• a diagnosis of Alzheimers Disease
• have and a reliable study partner that can attend some study visits with you. 

The main study lasts 24 weeks, with the option to continue for another 24 weeks in an open-label phase where everyone receives the study medication, making the total duration up to 48 weeks.